Curated News
By: NewsRamp Editorial Staff
October 06, 2025
Redcare Pharmacy Q3 Sales Soar 25%, German Rx Jumps 82%
TLDR
- Redcare Pharmacy's 82% German Rx sales surge and 25% total growth provide investors with strong momentum and competitive advantage in the European e-pharmacy market.
- Redcare Pharmacy achieved 25% Q3 sales growth through organic expansion in both DACH and International segments, with Rx sales increasing 42% and customer base reaching 13.7 million.
- Redcare Pharmacy's growth expands access to affordable healthcare across Europe, improving medication availability and customer satisfaction with NPS scores exceeding 70.
- Redcare Pharmacy's German prescription sales skyrocketed 82% in Q3 while maintaining over 70 NPS, showing exceptional customer satisfaction alongside rapid business expansion.
Impact - Why it Matters
This news matters because Redcare Pharmacy's explosive growth, particularly in prescription medications, signals a major shift in how Europeans access healthcare. As the leading e-pharmacy across seven countries, their 82% surge in German Rx sales demonstrates consumers' growing comfort with digital healthcare solutions. This trend reflects broader changes in healthcare delivery, where convenience, accessibility, and digital integration are becoming increasingly important. For investors, the sustained 25%+ growth across all markets and the reaffirmed full-year guidance indicate strong operational execution and market position. For consumers, Redcare's success means more accessible pharmaceutical services, potentially lower prices through competition, and improved healthcare convenience. The company's growing customer base of 13.7 million and improved NPS score above 70 suggest high satisfaction with their services, which could accelerate the digital transformation of pharmacy services across Europe.
Summary
Redcare Pharmacy N.V., Europe's leading e-pharmacy operating across seven countries including Germany, Austria, Switzerland, Belgium, Italy, France, and the Netherlands, has reported impressive third-quarter 2025 results with total sales surging 25% to EUR 719 million. The company demonstrated remarkable strength across both its reporting segments, with DACH achieving 25.2% growth and International markets growing 25.4%, all fully organic. Particularly noteworthy was the explosive growth in prescription medication sales (Rx), which jumped 42.3% to EUR 272 million, with German Rx sales skyrocketing 82.1% to EUR 126 million. This sustained positive performance across both Rx and non-Rx categories underscores the company's market leadership and operational excellence.
CEO Olaf Heinrich emphasized the company's strong Q3 momentum, particularly highlighting the double-digit quarter-over-quarter growth in German prescription medications. The company's growth remains profitable and cash-generative, with Q3 EBITDA lifting the year-to-date margin already into the full-year guidance range of 2-2.5%. Redcare Pharmacy also reported significant customer metrics improvements, adding 200,000 active customers to reach 13.7 million total, while the net promoter score (NPS) improved substantially to well over 70, up from 64 in the first half of the year. The company reaffirmed all elements of its full-year guidance, expressing confidence in achieving at least EUR 500 million in Rx sales for the full year, supported by accelerated German Rx growth and the customary seasonal uplift expected in Q4 order volumes.
Year-to-date performance remains equally impressive, with total sales up 27% to EUR 2.15 billion, representing a EUR 450 million increase. Non-Rx sales showed solid growth of 17% to EUR 448 million in Q3 and 18% year-to-date to EUR 1.4 billion, while German Rx sales year-to-date have grown an astonishing 122% to EUR 348 million. Management confirmed financial steering remains fully stable during the current transition period, with continuity ensured until the appointment of a new CFO. The company will release its full interim report on October 29, 2025, providing more detailed financial insights. The original release can be viewed on www.newmediawire.com, where investors and stakeholders can access comprehensive financial data and management commentary.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Redcare Pharmacy Q3 Sales Soar 25%, German Rx Jumps 82%
